CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 357 enrolled
Drug / intervention
AGN-199201 Dose A +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01735201
NCT01735201Phase 2Completed
CompareCT.gov

AGN-199201 for the Treatment of Erythema With Rosacea

Allergan·interventional·Posted Nov 28, 2012·Updated Nov 18, 2019

In Brief

A Phase 2 clinical trial evaluating AGN-199201 Dose A, AGN-199201 Dose B, and 2 other interventions for Rosacea and Erythema. Completed, enrolled 357 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea, Erythema
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 28, 2012
Enrollment StartDec 1, 2012
Primary CompletionMay 1, 2013
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.6 years ago

Interventions

AGN-199201 Dose Adrug

AGN-199201 Dose A applied once or twice daily to the face for 28 days.

AGN-199201 Dose Bdrug

AGN-199201 Dose B applied once or twice daily to the face for 28 days.

AGN-199201 Dose Cdrug

AGN-199201 Dose C applied once or twice daily to the face for 28 days.

AGN-199201 Vehicledrug

AGN-199201 Vehicle applied once or twice daily to the face for 28 days.